TimesSquare Capital Management LLC Has $24.33 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

TimesSquare Capital Management LLC raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 45.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,666,065 shares of the company's stock after purchasing an additional 523,455 shares during the quarter. TimesSquare Capital Management LLC owned 1.91% of Day One Biopharmaceuticals worth $24,325,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company's stock worth $27,000 after purchasing an additional 1,262 shares in the last quarter. Amalgamated Bank grew its position in shares of Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company's stock valued at $106,000 after acquiring an additional 2,268 shares during the period. Exchange Traded Concepts LLC increased its position in Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company's stock worth $147,000 after buying an additional 2,554 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Day One Biopharmaceuticals by 8.8% during the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company's stock worth $152,000 after acquiring an additional 995 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Day One Biopharmaceuticals by 9.7% in the 3rd quarter. Principal Financial Group Inc. now owns 17,781 shares of the company's stock valued at $218,000 after acquiring an additional 1,569 shares during the period. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Stock Down 3.9 %

DAWN traded down $0.67 on Wednesday, hitting $16.41. The company's stock had a trading volume of 602,920 shares, compared to its average volume of 888,000. Day One Biopharmaceuticals, Inc. has a 12 month low of $9.67 and a 12 month high of $18.07. The firm has a market cap of $1.43 billion, a P/E ratio of -6.89 and a beta of -1.44. The company's 50 day simple moving average is $15.46 and its 200-day simple moving average is $14.17.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). Equities analysts predict that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an "overweight" rating in a research report on Monday, April 22nd. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating for the company in a report on Tuesday, February 27th. HC Wainwright reduced their target price on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday. Wedbush reaffirmed an "outperform" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday. Finally, Needham & Company LLC reissued a "buy" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $37.67.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the business's stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company's stock, valued at $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Samuel C. Blackman sold 2,258 shares of Day One Biopharmaceuticals stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares of the company's stock, valued at $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jeremy Bender sold 70,051 shares of the business's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the completion of the transaction, the chief executive officer now owns 651,762 shares in the company, valued at approximately $11,653,504.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 195,247 shares of company stock worth $3,376,817. 8.40% of the stock is currently owned by insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.